Quantitative \(^{18}\)F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer

WENCHAO MA\(^1\)\(^-\)\(^3\), MINSHU WANG\(^1\)\(^-\)\(^3\), XIAOFENG LI\(^1\)\(^-\)\(^3\), HUI HUANG\(^1\)\(^-\)\(^3\), YANJIA ZHU\(^1\)\(^-\)\(^3\), XIUYU SONG\(^1\)\(^-\)\(^3\), DONG DAI\(^1\)\(^-\)\(^3\) and WENGUI XU\(^1\)\(^-\)\(^3\)

\(^1\)Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital;
\(^2\)National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy;
\(^3\)Tianjin Clinical Research Center for Cancer, Hexi, Tianjin 300060, P.R. China

Received December 26, 2016; Accepted October 13, 2017

DOI: 10.3892/ol.2018.9166

Abstract. The aim of the present study was to investigate the prognostic value of quantitative \(^{18}\)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) parameters for patients with non-small cell lung cancer (NSCLC). The present study conducted a retrospective review of the medical records of 203 patients with NSCLC, of which 193 patients underwent baseline \(^{18}\)F-FDG PET/CT prior to initial therapy. Multivariate analyses using Cox's proportional hazards regression were performed for the assessment of the association between initial PET/CT measurements and overall survival (OS). The multivariate models were adjusted for sex, age, smoking status, disease stage, standardized uptake value (SUV), standardized uptake value corrected for lean body mass (SUL), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and standard deviation of SUV (SD). Kaplan-Meier (K-M) estimator curves were constructed following the formation of three approximately equal-sized groups using tertiles for each PET/CT measurement (n=65, 64 and 64). OS curves were plotted using K-M estimator curves. Results demonstrated significant associations between OS and MT\(V_{\text{PET}}\), MT\(V_{2.5}\), MT\(V_{25}\%), MT\(V_{42}\%) and TL\(G_{\text{PET}}\); however, no significant associations were identified between OS and SD, MTV50\%, TV\(G_{2.5}\), TL\(G_{2.5}\), all SUV and SUL. Subgroup analyses according to pathology demonstrated that there were statistically significant associations between OS and stage (P<0.001), MTV50\% (P=0.002) and MTV42\% (P=0.004) in the adenocarcinoma group, and SUL\(_{\text{mean}}\) (P=0.010), MTV25\% (P=0.005) and MTV42\% (P=0.001) in the squamous cell carcinoma group; however, no significant differences were identified between any other group. Furthermore, there was a significant association between OS and MT\(V_{42}\%\) (P=0.02) and MT\(V_{50}\%\) (P=0.04) in the early-stage group; however, no significant differences were identified in the advanced-stage group. K-M estimator curve analyses demonstrated that the pathology (P=0.01), stage (P<0.001) and all PET metabolic parameters with the exception of SD were significantly associated with OS (P<0.05). No significant associations were demonstrated between SD and OS. In conclusion, \(^{18}\)F-FDG PET/CT MTV\(_{\text{PET}}\), MT\(V_{2.5}\)\(,\) MT\(V_{25}\%)\(,\) MT\(V_{42}\%)\(,\) and TL\(G_{\text{PET}}\)\(\_\text{CAR}\) exhibit prognostic values with regard to OS. Overall, selection of appropriate metabolic parameters may predict NSCLC prognosis.

Introduction

Lung cancer is the leading cause of cancer-associated mortality worldwide, of which non-small cell lung cancer (NSCLC) accounts for ~80% of all cases (1). Survival rate analyses of patients with lung cancer have become a key point of interest in recent years. Survival rates of patients with NSCLC are associated with early diagnosis and treatment, as well as a number of other factors including the stage of the disease, which is based on the evaluation of the tumor (T), node (N) and metastasis (M) grading system, and the assignment of disease staging (I-IV) (2). Collectively, these factors are important in determining patient prognosis; however, it is important to note that numerous patients presenting at early stage are capable of relapse (3,4).

Currently, lung cancer-associated pathological differences are not yet well-established; however, \(^{18}\)F-fluorodeoxyglucose (\(^{18}\)F-FDG) positron emission tomography (PET)/computed tomography (CT) may be a useful tool in observing tumor characteristics and patient prognosis non-invasively. Metabolic tumor burden measurements including metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have been developed previously, which provide information on tumor volume and metabolic activity, respectively (5,6). Despite previous studies demonstrating the superiority of MTV and/or TLG calculations compared with the maximum standardized uptake value (SUV\(_{\text{max}}\)) for measuring tumor burden, the practicality of using MTV and/or TLG has not been without controversy (7). In
addition, PET Response Criteria In Solid Tumors (PERCIST) 1.0 recommends that the standardized uptake value corrected for lean body mass (SUL) should replace the traditional standardized uptake value (SUV); however, an association between SUL and long-term survival rates has not yet been demonstrated. Furthermore, intratumoral heterogeneity characterized by PET has demonstrated a predictive and prognostic value over SUV measurements (8, 9). In the present study, the prognostic value of \[^{18}\text{F}]\text{FDG PET/CT parameters, including SUV}_{\text{max}}, \text{SUV}_{\text{mean}}, \text{SUL}_{\text{peak}}, \text{MTV}, \text{and TLG}, were investigated for the management of patients with NSCLC.}

**Materials and methods**

**Patients.** The present study was approved by the Institutional Review Board of Tianjin Medical University Cancer Institute and Hospital (Tianjin, China). A retrospective review of the medical records of patients with NSCLC who had undergone baseline \[^{18}\text{F}]\text{FDG-PET/CT prior to initial therapy was conducted. Written informed consent was obtained from each patient prior to each PET/CT scan. All patients were followed up for ≥5 years after surgery. A total of 203 consecutive patients (62.05±10.78 years) who were pathologically diagnosed with NSCLC at Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) between February 2004 and August 2010 were included in the present study. Inclusion criteria included: i) All patients had a pre-therapy baseline PET/CT scan; ii) primary lung cancer was treated using surgery; iii) patients had no history or concurrent diagnosis of another type of cancer; and iv) patients were followed up for ≥5 years after surgery.

**PET/CT protocol.** All patients were required to fast for ≥6 h prior to the 60 min uptake period of \[^{18}\text{F}]\text{FDG (3.70–4.81 mBq/kg). Blood glucose was measured using a finger blood test (CNGQFOC8, UltraVue; Johnson & Johnson, Shanghai, China) prior to the injection to ensure that levels were <6.8 mmol/l. Scanning was performed from head to thigh using a PET/CT system (Discovery ST4; GE Healthcare, Chicago, IL, USA). The protocol included an initial CT scan followed by PET acquisition. The initial CT was performed at 120 kV and 100 mA, and the slice thickness was 5 mm. PET data were obtained in three-dimensional mode with an acquisition time of 2 min for each bed, with between 6 and 8 bed positions being completed. PET images were reconstructed with attenuation correction calculated from co-registered CT images using ordered subset expectation maximization (OSEM) iterative algorithm (10). Following completion of acquisition, separate PET images, CT images and fused PET/CT data were available for review in coronal, sagittal and axial planes using an Xeleris review station (GE Healthcare) and PET volume computerized assisted reporting (PETVCAR) on an Advantage Workstation (version 4.6; GE Healthcare.) (11) was used to analyze results.

**Image analysis.** Images were observed using a Xeleris review station, which allowed visualization of PET/CT and fused sections in transverse, coronal and sagittal planes. Images were interpreted by two board-certified nuclear medicine physicians who were informed of patients' clinical data at the time of scanning; however, they were not aware of the patient outcome.

**Metabolic characteristics of lung cancer using \[^{18}\text{F}]\text{FDG uptake assisted in defining the volume of interest (VOI) metabolic parameter, which was created over the lung cancer (>0.5 cm in diameter) using PETVCAR on an Advantage Workstation (version 4.6; GE Healthcare). PETVCAR is an automated segmentation software system that uses an iterative adaptive algorithm to detect the threshold level; this separates the target volume from the background tissue by determining the SUV_{\text{max}} and the SUV_{\text{mean}} within a target volume, with a weighting factor of 0.5 (12). A VOI was placed around the primary tumor to ensure that all the tumor activity was within the VOI, while avoiding regions of physiologically increased activity (e.g. \[^{18}\text{F}]\text{FDG uptake in the heart). If high-activity structures could not be avoided, they were removed prior to analysis.}

When segmentation is at an estimated threshold, PETVCAR was used to calculate the following parameters for lung cancer VOI: SUV_{\text{max}} and SUV_{\text{mean}} were defined as the maximum SUV and SUL, respectively, within the target volume, and were derived from the single voxel with the highest tracer uptake within the VOI; SUV_{\text{mean}} and SUL_{\text{mean}} were calculated as the sum of SUV or SUL in each voxel within the target volume, divided by the number of voxels within the target volume, which were derived from all voxels within the VOI, assuming that it reflected the tracer uptake within that VOI; SUL_{\text{peak}} was defined as the largest possible mean value of a 1 cm³ spherical region of interest (ROI) within a tumor; MTV_{\text{PETCAR}} represented the contoured tumor tissues with accumulation of \[^{18}\text{F}]\text{FDG; TLG}_{\text{PETCAR}} was defined as the product of SUV_{\text{mean}} and MTV; SD was defined as the standard deviation of SUV.

Once segmentation had reached the maximum percentage threshold, PETVCAR was used to calculate several parameters for lung cancer VOI, including MTV2.5, MTV42, MTV50 and MTV75%, which were defined as tumor volume with an absolute threshold of 25, 42, 50 and 75% of the histogram of SUV_{\text{max}}, respectively.

When segmentation was at a fixed threshold (SUV≥2.5), PETVCAR was used to calculate several parameters for lung cancer VOI, including MTV2.5, and TLG2.5. MTV2.5 was defined as tumor volume with SUV >2.5 being the absolute threshold, whereas TLG2.5 was defined as the product of SUV_{\text{mean}} and MTV2.5.

**Lung cancer staging.** Disease staging was determined according to the TNM staging system and PET/CT results. Brain magnetic resonance imaging scans were performed in order to detect any potential brain metastases. If patients had undergone a mediastinoscopy, these results superseded the imaging results in mediastinum nodal staging. Tumor location was divided into right upper lung, right middle lung, right lower lung, left upper lung, left lower lung and double lung. According to the different pathological types, all patients with NSCLC were divided into three groups: Adenocarcinoma, squamous cell carcinoma and others.

**Statistical analysis.** Multivariate analyses using Cox's proportional hazards regression were performed for the assessment.
of the association between initial PET/CT measurements and overall survival (OS). Multivariate models were adjusted for sex, age, smoking status, disease staging, SUV\textsubscript{mean}, SUV\textsubscript{max}, SUV\textsubscript{peak}, SUV\textsubscript{mean}, SUV\textsubscript{max}, SUV\textsubscript{peak}, MTV\textsubscript{PETVCAR}, MTV\textsubscript{2.5}, MTV\textsubscript{25\%}, MTV\textsubscript{42\%}, MTV\textsubscript{50\%}, MTV\textsubscript{75\%}, TLG\textsubscript{PETVCAR}, TLG\textsubscript{2.5} and SD. K-M estimator curves were constructed following the production of three approximately equal-sized groups (n=65, 64 and 64) using tertiles from each PET/CT measurement, and the differences in survival rates within these groups were assessed using the log-rank test. OS curves were plotted using the K-M estimator method, and the differences in survival rates within these groups were assessed using the log-rank test. Statistical analysis was used to assess whether these new measurements provided any additional information regarding patient survival rates compared with the risk factor provided by assessing the cancer stage. OS was calculated from the date of surgery to the last follow-up or the time of patient mortality. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS (version 17.0; SPSS, Inc., Chicago, IL, USA).

Results

Patient characteristics. In total, 203 patients fulfilled the inclusion criteria, of which 114 were adenocarcinoma, 66 were squamous cell carcinoma, 10 were adenosquamous carcinoma, 4 were large cell carcinoma, 3 were atypical carcinoid, 2 were poorly differentiated mucous epidermoid carcinoma, 2 were lymphoepithelioma-like carcinoma and 2 were sarcomatoid carcinoma (Table I).

Survival rate analyses. The 5-year survival rate of 203 patients was 57±3\% (mean ± standard error of the mean). The 95\% confidence interval for the 5-year cumulative survival rate of patients was 62.88 and 51.11\%.

Multivariate models were adjusted for different pathological types, sex, age, smoking status, disease stage and tumor location in 203 patients. Results demonstrated a significant association between OS and pathological types (P=0.01), and also stage (P<0.001); however, no significant differences were identified between OS and sex, age, smoking status and/or location. In total, 9 patients with adenocarcinoma and 1 patient with squamous cell carcinoma were associated with undetectable levels of \(^{18}\)F-FDG uptake (Table II); therefore \(^{18}\)F-FDG parameters were measured in 193 patients. Results demonstrated significant associations between OS and disease stage [P<0.001; odds ratio (OR)=1.414], MTV\textsubscript{PETVCAR} (P=0.002; OR=0.987), MTV\textsubscript{2.5} (P=0.009; OR=0.948), MTV\textsubscript{25\%} (P=0.003; OR=1.055), MTV\textsubscript{42\%} (P=0.04; OR=0.907) and TLG\textsubscript{PETVCAR} (P=0.003; OR=1.016). Results presented little difference between OR values and survival rates, which suggests that the influence of various parameters on survival rates are similar; however, no significant associations were identified between OS and MTV\textsubscript{50\%}, MTV\textsubscript{75\%}, TLG\textsubscript{PETVCAR}, TLG\textsubscript{2.5} and SD within each group, respectively. Results obtained from the adenocarcinoma group demonstrated significant associations between OS and stage (P<0.001), MTV\textsubscript{50\%} (P=0.002) and MTV\textsubscript{42\%} (P=0.004). Results obtained from the squamous cell carcinoma group demonstrated significant associations between OS and SUV\textsubscript{mean} (P=0.010), MTV\textsubscript{25\%} (P=0.005) and MTV\textsubscript{42\%} (P=0.001). Results obtained from the other groups demonstrated no significance between OS and all other parameters.

In total, 193 patients were divided into early-stage (I and II; n=140) and late-stage (III and IV; n=53). Cox's multivariate analyses were performed with regard to OS adjusted for stage, SUV\textsubscript{mean}, SUV\textsubscript{max}, SUV\textsubscript{peak}, MTV\textsubscript{PETVCAR}, MTV\textsubscript{2.5}, MTV\textsubscript{25\%}, MTV\textsubscript{42\%}, MTV\textsubscript{50\%}, MTV\textsubscript{75\%}, TLG\textsubscript{PETVCAR}, TLG\textsubscript{2.5} and SD within each group, respectively. Results from the early-stage group demonstrated significant associations between OS, MTV\textsubscript{25\%} (P=0.02; OR=1.572) and MTV\textsubscript{50\%} (P=0.04; OR=0.871).

### Table I. Patient characteristics.

| Variables | No. of patients | Proportion, % |
|-----------|----------------|--------------|
| Sex       |                |              |
| Male      | 116            | 57.1         |
| Female    | 87             | 42.9         |
| Histology |                |              |
| Adenocarcinoma | 114  | 56.2         |
| Squamous cell carcinoma | 66    | 32.5         |
| Others    | 23             | 11.3         |
| Smoking history |         |              |
| Adenocarcinoma | 44    | 38.6         |
| Squamous cell carcinoma | 58    | 87.9         |
| Others    | 17             | 73.9         |
| Stage     |                |              |
| IA        | 72             | 35.5         |
| IB        | 32             | 15.8         |
| II        | 33             | 16.3         |
| IIIB      | 9              | 4.4          |
| IIIA      | 34             | 16.7         |
| IIIB      | 7              | 3.4          |
| IV        | 16             | 7.9          |
| Tumor location |        |              |
| RUL       | 60             | 29.6         |
| RML       | 17             | 8.4          |
| RLL       | 36             | 17.7         |
| LUL       | 48             | 23.6         |
| LLL       | 41             | 20.2         |
| DL        | 1              | 0.5          |

RUL, right upper lung; RML, right middle lung; RLL, right lower lung; LUL, left upper lung; LLL, left lower lung; DL, double lung.
Patients with squamous cell carcinoma or adenocarcinoma exhibited significantly increased median survival rates compared with patients within the others group (89.37, 81.80 and 18.93 months, respectively; \( P=0.009 \); Fig. 1).

The median survival rate of patients was 83.6 months at stage IA, >60 months at stage IB, 67.07 months at stage IIA, >60 months at stage IIB, 57.60 months at stage IIIA, 27.13 months at stage IIIB and 32.5 months at stage IV. These results were statistically significant \( (P=0.013) \). The median survival rates for patients was 88.67 months at stage I, 67.07 months at stage II, 48.05 months at stage III and 32.5 months at stage IV. These results were also statistically significant \( (P=0.02) \). The median survival rate of patients who presented at an early-stage was significantly increased compared with patients who presented at a late stage (88.67 vs. 40.33 months, respectively; \( P=0.02 \)). The survival curves are presented in Fig. 2. K-M estimator curves were constructed following the formation of three approximately equal-sized groups using tertiles from PET/CT indices. Results are presented in Table III, with representative survival rate curves presented in Fig. 3. Results demonstrated statistical significance among all PET/CT indices with the exception of SD. Furthermore, results demonstrated that as OS decreases, metabolism increases.

| Status    | Time, months | Stage   | Smoking status | Sex   | Age, years |
|-----------|--------------|---------|----------------|-------|------------|
| Alive     | 22.57        | IIIA    | Yes            | Female| 57         |
| Deceased  | 24.90        | IA      | No             | Male  | 58         |
| Deceased  | 38.50        | IIIA    | Yes            | Male  | 47         |
| Alive     | 39.33        | IIIA    | Yes            | Female| 62         |
| Deceased  | 64.30        | IA      | Yes            | Female| 47         |
| Deceased  | 64.33        | IV      | Yes            | Female| 57         |
| Deceased  | 83.67        | IA      | Yes            | Female| 50         |
| Alive     | 94.60        | IA      | No             | Male  | 57         |
| Alive     | 108.00       | IA      | Yes            | Female| 55         |

PET, positron emission tomography; NSCLC, non-small cell lung cancer.

**Table II. Characteristics of PET-negative patients with NSCLC.**

**Figure 1.** Survival rate curves for patients with SCC, AD and others. SCC, squamous cell carcinoma; AD, adenocarcinoma; Cum, cumulative.

**Figure 2.** Survival rate curves for patients with NSCLC. (A) Stage IA, IB, IIA, IIB, IIIA, IIIB and IV. (B) Stages I-IV. (C) Early and late stage. Cum, cumulative.
PET metabolic index | Log-rank test | P-value  
--- | --- | ---  
MTV\textsubscript{PETVCAR} | 21.709 | <0.001  
MTV2.5 | 21.389 | <0.001  
MTV25\% | 28.489 | <0.001  
MTV42\% | 19.709 | <0.001  
MTV50\% | 20.099 | <0.001  
MTV75\% | 18.154 | <0.001  
TLG\textsubscript{PETVCAR} | 27.084 | <0.001  
TLG 2.5 | 30.520 | <0.001  
SUV\textsubscript{max} | 7.942 | 0.019  
SUV\textsubscript{mean} | 8.224 | 0.016  
SUL\textsubscript{max} | 15.337 | <0.001  
SUL\textsubscript{mean} | 7.628 | 0.022  
SUL\textsubscript{peak} | 17.489 | <0.001  
SD | 4.591 | 0.101  

PET, positron emission tomography; CT, computerized tomography; MTV, metabolic tumor volume; PETVCAR, PET volume computerized assisted reporting; TLG, total lesion glycolysis; SUV, standardized uptake volume; SUL, standardized uptake value corrected for lean body mass; SD, standard deviation of standardized uptake volume; max, maximum.

Discussion

In the present study, the prognostic value of \textsuperscript{18}F-FDG PET/CT metabolic parameters was investigated. The Cox's multivariate models demonstrated that there were significant associations between OS and various pathological parameters and disease stages. The results of the present study are in agreement with those of previous studies, which demonstrate that TNM staging may serve as a prognostic marker for patients with lung cancer (2,13-15). However, results demonstrated no significant associations between OS and sex, age, smoking status or tumor location. This is not in agreement with previous studies, which have demonstrated an association between these parameters and survival rates (16-18). A number of studies have discussed the association between tumor location regarding pre-treatment images and prognosis; however, the results differed. Lally et al (19) reported that the location of the main bronchus was one of primary risks associated with mortality; however, Bandoh et al (20) demonstrated that no significant difference in prognosis was identified between the peripheral and central types of lung cancer.

Cox's multivariate analyses using PET metabolic indices demonstrated significant associations between OS and MTV\textsubscript{PETVCAR}, MTV2.5, MTV25\%, MTV42\% or TLG\textsubscript{PETVCAR}; however, no significant differences were identified between OS and MTV50\%, MTV75\%, TLG2.5, or all SUV and SUL. Therefore, these results suggest that MTV and TLG are improved prognostic markers for patients with lung cancer compared with SUV and SUL measurements. \textsuperscript{18}F-FDG PET/CT-based imaging parameters including SUV\textsubscript{max}, MTV and TLG have been previously suggested as potential prognostic markers for various types of neoplasm (21-24). This may be due to SUV and SUL being a single voxel value, and therefore may not represent total tumor metabolism. However, accumulating evidence suggests that MTV and TLG are superior in assessing NSCLC response compared with SUV\textsubscript{max}; however, the efficient determination of these values is not yet well-established (1,25-29). Results from recent studies demonstrate that MTV and TLG were computed using a maximum percentage threshold of 40-50\% (30,31). However, other studies used a fixed SUV threshold, most commonly SUV2.5, where SUV>2.5 is the absolute threshold (TLG2.5 or MTV2.5), particularly for segmentation of lung tumors (32-34). Increasing interest in volumetric indices has led to the development of commercially available tools, for example PETVCAR, which enables the rapid and simple measurement of numerous indices for tumor analysis, including various threshold values of MTV and TLG (typically, 41-70\% of SUV\textsubscript{max} within the tumor) (35). However, there are also several conflicting results regarding the prognostic value of volumetric parameters in NSCLC (36,37). Furthermore, the association between survival rates and SUL remains unclear.

Results from subgroup data with regard to pathology analysis demonstrated that patients with adenocarcinoma exhibited a significant association between OS and stage, MTV50% or MTV42%; patients with squamous cell carcinoma exhibited significant associations between OS and SUL\textsubscript{mean}, MTV25% or MTV42%; patients assigned to the others group did not exhibit any significant associations. Early stage Cox's multivariate analyses demonstrated significant associations between OS and MTV42% or MTV50%; however, no significant differences were identified in late-stage Cox's multivariate analyses. Therefore, MTV50% and/or MTV42% in adenocarcinoma or early stage, and MTV25% and/or MTV42% in squamous cell carcinoma may provide an improved prediction of prognosis compared with other metabolic indexes (SUV\textsubscript{mean}, SUV\textsubscript{max}, SUL\textsubscript{mean}, SUL\textsubscript{max}, MTV\textsubscript{PETVCAR}, MTV2.5, MTV75%, TLG\textsubscript{PETVCAR}, TLG2.5 and SD) for patients with NSCLC. In 2013, Machtay et al (38) conducted a large prospective multi-center study investigating 250 patients with stage III NSCLC and demonstrated that pretreatment SUV\textsubscript{max} was not associated with survival rates.

K-M estimator analyses demonstrated that the pathology, stage and all PET metabolic parameters with the exception of SD were significantly associated with OS. These results are not in agreement with those obtained from the Cox's multivariate analyses. The K-M survival rate curves of a number of index had a common crossover point, that may have lead to different results of K-M estimator analyses and the Cox. Furthermore, previous studies investigating the use of PET intratumoral heterogeneity characterization demonstrated a potential added predictive and prognostic value over simple SUV measurements (8,9). However, SD demonstrated no significant association with OS in the Cox's multivariate analyses or the K-M log-rank test.

It is important to note that the present study has several limitations. First, the retrospective nature has resulted in numerous
biases including the fact that patient characteristics may not be representative of an entire population. Secondly, the present study was performed at a single hospital, and therefore results are not representative of national or international populations. Thirdly, all patients had undergone primary lung cancer surgery, which may induce results bias. Therefore, prospective large-scale multicenter studies with longer follow-up periods and patients that have undergone various types of therapy are required to identify the prognostic markers of post-surgical outcomes.

In conclusion, ¹⁸F-FDG PET/CT quantitative parameters including \( \text{MTV}_{\text{PET/CT}} \), \( \text{MTV2.5} \), \( \text{MTV25} \), \( \text{MTV42\%} \) and \( \text{TLG}_{\text{PET/CT}} \) exhibit prognostic value for OS; however, \( \text{MTV50} \), \( \text{MTV75\%} \), \( \text{TLG2.5} \), SD, all SUV and SUL do not. There were certain differences within the subgroups. Selection of appropriate metabolic parameters may be useful in predicting prognosis for future patients with NSCLC.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of Tianjin (grant no. 16JCZDJC35200) and the Tianjin Municipal Bureau of Health Science and Technology Fund (grant no. 2013KZ090).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

WX and WM designed this study and prepared this manuscript; MW, XL, HH, YZ, XS, DD collected clinical samples and analyzed data.

Ethics approval and consent to participate

The present study was approved by the Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) and written informed consent was obtained from all patients.

Patient consent for publication

Written informed consent was obtained from all participants prior to publication.
Competing interests

The authors declare that they have no competing interests.

References

1. Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kimoshita T, et al: Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. Eur J Radiol 81: 4179-4184, 2012.

2. UyBico SJ, Wu CC, Suh RH, Le NH, Brown K and Krishnam MS: Lung cancer staging essentials: The new TNM staging system and potential imaging pitfalls. Radiographics 30: 1163-1181, 2010.

3. van Rens MT, de la Rivière AB, Elbers HR and van Den Bosch JM: Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117: 374-379, 2000.

4. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-3559, 2008.

5. Lee P, Weeraratna S, Lavori PW, Harra W, Maxim PG, Le QT, Wakelee HA, Donington JS, Graves EE and Loo BW Jr: Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 69: 328-333, 2007.

6. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Stephens RJ, Dunant A, Long J, Xu Z, Zhang YJ, Chao KH, Liu L and Yu XJ: Metabolic tumor burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging 41: 1093-1102, 2014.

7. Collard S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, et al: Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non small cell lung cancer. Eur J Nucl Med Mol Imaging 39: 27-38, 2012.

8. Chung HW, Lee KY, Kim HJ, Kim WS and So Y: FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol 140: 89-98, 2014.

9. Melloni G, Gajate AM, Besset JH, Gallivanne F, Bandiera A, Lantini C, Murina P, Giannini L and Zannini P: New positron emission tomography derived parameters as predictive factors for recurrence in restaged stage I non-small cell lung cancer. Eur J Surg Oncol 39: 1254-1261, 2013.

10. Shim YM and Choi JY: Volume-based assessment by (18)F‑FDG PET in surgical patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol 25: 3348-3353, 2015.

11. Moule RN, Kayani I, Prior T, Lemon C, Godchild K, Sanghera B, Wong WL and Saunders MF: Adaptive 18fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer. Clin Oncol (R Coll Radiol) 23: 364-371, 2011.

12. Crivellaro C, Signorelli M, Guerra L, De Ponti E, Buda A, Dolci C, Pirovano C, Todde S, Fruscio R and Messa C: 18FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecol Oncol 127: 131-135, 2012.

13. Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.

14. Adebonojo SA, Bowser AN, Moritz DM and Corcoran PC: Impact of revised stage classification of lung cancer on survival: A military experience. Chest 115: 1507-1513, 1999.

15. Gaedge SM, Ramalingam SS and Kalemkerian GP: Treatment of limited stage small cell lung cancer. J Clin Oncol 21: 961-974, 2003.

16. Grivaux M, Zureik M, Marsal L, Asselain B, Peureux M, Chavallion JM, Prudhomme A, Carbonnelle M, Garaert P, Maury B, et al: Five-year survival for lung cancer patients managed in general hospitals. Rev Mal Respir 26: 37-44, 2009 (In French).

17. Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 350: 379-392, 2004.

18. Socinski MA, Norris DE, Masters GA and Lilienbaum R: American College of Chest Physicians: Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123: (1 Suppl): 226S-243S, 2003.

19. Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, Wilson LD, Horton JK, Detetterbeck FC, Miller AA, et al: Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the surveillance, epidemiology, and end results database. Lung Cancer 64: 226-231, 2009.

20. Bandoh S, Fujita U, Ueda Y, Fukunaga Y, Doi T, Hojo S, Yang Y, Yamaji Y, Takahara J and Ishida T: Expression of carcinoembryonic antigen in peripheral-or central-located small cell lung cancer: Its clinical significance. Jpn J Clin Oncol 31: 305-310, 2001.

21. Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, Kim EE and Lee DS: Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: A systematic review and meta-analysis. J Nucl Med 55: 884-890, 2014.

22. Guy MS, Jacob C, McDonald SD, Dowdy YG and Kardan A: 18F-FDG PET/CT metabolic variability in functioning oncocyto proliferative adenohypophysis with brown tumors. Clin Nucl Med 39: 393-395, 2014.

23. Xia HX, Chen T, Wang WQ, Wu CT, Liu C, Long J, Xu Z, Zhang YJ, Chao KH, Liu L and Yu XJ: Metabolic tumor burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Mol Imaging 41: 1093-1102, 2014.

24. Adenri Jr, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, et al: Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non small cell lung cancer. Eur J Nucl Mol Imaging 39: 27-38, 2012.

25. Chung HW, Lee KY, Kim HJ, Kim WS and So Y: FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol 140: 89-98, 2014.

26. Martini C, Gajate AM, Soscia E, Pedicini P, Gattozzi D, Musto P and Bandi A: Prognostic value of metabolic tumor burden on 18F-FDG PET in surgical patients with non small cell lung cancer. Acad Radiol 20: 32-40, 2013.

27. Hyeon SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shin YM and Choi JY: Volume-based assessment by (18)F‑FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 41: 50-58, 2014.

28. Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van den Heijden EH, Kaanders JH, Oyen WJ, Schuurmans OC and Cassink F: 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med 54: 1528-1534, 2013.

29. Vargyas HA, Burger JA, Goldman DA, Miccò M, Sosa RE, Weber W, Chi DS, Hricak H and Sala E: Volume‑based quantitative FDG PET/CT metrics and their association with optimal debulking and progression‑free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol 25: 3348-3353, 2015.

30. Giaccarino R, Manueto G, Simeon V, Nardelli A, Guariglia R, Cappabianche D, Sessia E, Pedicini P, Gattozzi D, Musto P and Storto G: 18F‑FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B‑cell lymphoma. Eur J Haematol 92: 382-389, 2014.

31. Lee JW, Kang CM, Choi HJ, Lee JW, Song SY, Lee JH and Lee JD: Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer. J Nucl Med 55: 898-904, 2014.

32. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, Song YS, Chung JK and Kang SB: Prognostic value of metabolic tumor volume measured by FDG PET/CT in patients with cervical cancer. Gynecol Oncol 120: 270-274, 2011.

33. Seol YM, Kwon BR, Song MK, Choi YJ, Shin HJ, Chung JS, Cho GJ, Lee JC, Lee BJ, Wang SG, et al: Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 49: 201-208, 2010.
35. Moon SH, Hyun SH and Choi JY: Prognostic significance of volumebased PET parameters in cancer patients. Korean J Radiol 14; 1-12, 2013.
36. Vu CC, Matthews R, Kim B, Franceschi D, Billinger TV and Moore WH: Prognostic value of metabolic tumor volume and total lesion glycolysis from $^{18}$F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Nucl Med Commun 34: 959-963, 2013.
37. Kim K, Kim SJ, Kim JJ, Kim YS, Pak K and Kim H: Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun 33: 613-620, 2012.

38. Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, et al: Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: Results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol 31: 3823-3830, 2013.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.